What Days Should You Take Letrozole for Fertility?

Letrozole for fertility is typically taken for five consecutive days early in your menstrual cycle, most commonly starting on either cycle day 3 or cycle day 5. The “right” days depend on your diagnosis, your doctor’s protocol, and whether you are trying to conceive naturally, doing intrauterine insemination (IUI), or preserving fertility before cancer treatment. The standard window is straightforward, but the reasoning behind different start days, extended schedules, and special situations is worth understanding.

The Standard Five-Day Window

In most fertility clinics, letrozole is prescribed as a 2.5 mg tablet taken once daily for five days. The two most common schedules are days 3 through 7 or days 5 through 9 of your cycle, where day 1 is the first day of your period. Both schedules aim to temporarily lower estrogen during the early follicular phase, which prompts your brain to release more follicle-stimulating hormone (FSH) and drive one or more follicles to grow to a size capable of ovulation.

A study of over 500 women with polycystic ovary syndrome (PCOS) compared starting letrozole on cycle day 3 versus cycle day 5, with each group taking the drug for five days.¹ Both schedules produced viable follicles and pregnancies, and many clinics choose one start day over the other based on institutional preference rather than a dramatic difference in outcomes. If your doctor says “start on day 3,” that is just as evidence-based as a clinic that says “start on day 5.”

One practical difference: starting on day 3 sometimes gives the medication a slight head start, which can matter if your clinic wants to see you for a monitoring ultrasound around day 10 or 11. Starting on day 5 pushes the expected ovulation window a day or two later, which some clinics prefer because it gives the dominant follicle a bit more growing time before trigger. Neither approach has been shown to be clearly superior for pregnancy rates.

Extended Protocols

Some clinics experiment with giving letrozole for more than five days, particularly for women who do not respond well to the standard schedule. An extended regimen, often seven or ten days of letrozole, aims to give the ovaries a longer period of estrogen suppression and sustained FSH elevation. A randomized trial comparing a 10-day extended letrozole regimen to the conventional 5-day course in women with PCOS found that ovulation rates were slightly higher with the extended schedule (about 91% versus 80%), but the difference was not statistically significant.² Extended protocols remain less common and are generally reserved for cases where the standard five-day course has not produced adequate follicle growth.

Dose Escalation When Standard Days Are Not Enough

Before switching to a longer course or a different drug entirely, most doctors will first try raising the dose while keeping the same five-day schedule. The starting dose is usually 2.5 mg per day. If you do not develop a mature follicle on monitoring, the next cycle may bump you to 5 mg, and then 7.5 mg if needed.

How many women actually need dose increases? In one cohort study, roughly half of women with PCOS ovulated on 2.5 mg, about a third needed 5 mg, and around one in five required 7.5 mg.³ Another study found that only about a third of women ovulated on the first cycle of 2.5 mg, but when the remaining non-responders were escalated to 5 mg, roughly 63% of them responded, and escalating the remaining non-responders to 7.5 mg brought about 79% of those women to ovulation.⁴ The point is that not ovulating on your first letrozole cycle does not mean the drug has failed. The timing stays the same; only the dose changes.

Certain characteristics predict whether you will need a higher dose. Women with higher androgen levels, a very high anti-Müllerian hormone (AMH) level, or a higher LH-to-FSH ratio at baseline are more likely to resist the starting dose.⁵ If your bloodwork shows these patterns, your doctor may anticipate a need for dose escalation.

Random-Start Protocols for Fertility Preservation

The day-3-or-day-5 rule applies to women trying to conceive in a given cycle. For women facing cancer treatment who need to freeze eggs or embryos urgently, waiting for the start of a new period is often not an option. In these cases, letrozole can be started on essentially any day of the cycle, a so-called random-start protocol.

Research on random-start letrozole cycles in breast cancer patients found that stimulation could begin at any point in the cycle without compromising the number of mature eggs retrieved or the quality of embryos produced.⁶ Most of these random-start cycles happened to begin in the luteal phase (the second half of the cycle), and outcomes were comparable to conventional-start cycles.⁷ An earlier study confirmed that fertilization rates were not compromised when ovarian stimulation was started at a random cycle date in letrozole-based protocols.⁸

Letrozole plays a dual role in these cancer-related protocols. Beyond stimulating follicle growth, it keeps estrogen levels low during ovarian stimulation, which is especially important for hormone-sensitive cancers like many breast cancers. The random-start approach uses higher gonadotropin doses alongside letrozole, so it is a more intensive protocol than simple ovulation induction, but the flexibility to start any day can save critical time before chemotherapy begins.

Why Letrozole Is Favored in PCOS

If you have PCOS, your doctor likely reached for letrozole first, and the evidence supports that choice regardless of whether you start on day 3 or day 5. A large multicenter trial published in the New England Journal of Medicine found that women with PCOS who took letrozole had cumulative live birth rates of about 28%, compared to about 19% for clomiphene citrate.⁹ A meta-analysis of nine randomized controlled trials confirmed that letrozole produced significantly higher ovulation, pregnancy, and live birth rates than clomiphene in PCOS populations.¹⁰

Part of the advantage is that letrozole tends to produce a single dominant follicle rather than multiple follicles. One study found monofollicular development in about 77% of letrozole cycles versus about 53% of clomiphene cycles.¹¹ Fewer follicles means a lower risk of twins or higher-order multiples, which is a real safety consideration, especially for women with PCOS who tend to be more sensitive to ovarian stimulation.

Letrozole for Unexplained Infertility

Outside of PCOS, the picture is more nuanced. A scoping review found that letrozole-only protocols produced higher pregnancy rates in both PCOS and unexplained infertility groups compared to combination regimens.¹² However, a major trial comparing letrozole, clomiphene, and injectable gonadotropins in unexplained infertility found that letrozole produced lower live birth rates than gonadotropins (about 19% versus 32% per cycle), though its rates were not significantly different from clomiphene alone.¹³ On the plus side, the multiple-gestation rate with letrozole was about 13%, compared to 32% with gonadotropins alone.

A meta-analysis comparing letrozole to clomiphene specifically in IUI cycles for unexplained infertility suggested letrozole may improve dominant follicle development and reduce miscarriage rates.¹⁴ The bottom line for unexplained infertility: letrozole is a reasonable and lower-risk starting point, though injectable medications can push pregnancy rates higher at the cost of more monitoring and a higher chance of multiples.

What Happens After You Finish the Five Days

Once you take your last letrozole pill, the real action begins. Your clinic will typically schedule a monitoring ultrasound somewhere between cycle day 10 and day 14 to measure follicle size and endometrial thickness. The goal is to see at least one follicle approaching maturity.

Follicle size matters more than most patients realize. A study analyzing nearly 1,000 IUI cycles found that the highest pregnancy rates with letrozole occurred when the leading follicle measured 23 to 28 mm at the time of ovulation trigger.¹⁵ That is larger than many patients expect, especially those who have heard the general “18 mm is mature” guideline. A separate study of letrozole-IUI cycles pinpointed the optimal range at 19 to 21 mm, with both smaller and larger follicles associated with lower pregnancy rates in an inverted U-shaped curve.¹⁶ These ranges differ somewhat between studies, but the takeaway is consistent: triggering too early (when the follicle is still small) or waiting too long can both reduce your chances.

Letrozole also appears to promote more uniformly sized follicles during ovarian stimulation. In a randomized trial that added letrozole to a standard gonadotropin protocol, the letrozole group had significantly more large follicles (above 16 mm) at retrieval compared to placebo, even though the total follicle count was the same.¹⁷ More synchronous follicle growth means fewer “wasted” small follicles that never catch up.

Trigger Timing and Progesterone Levels

After your monitoring ultrasound confirms a mature follicle, you will likely receive an injection of human chorionic gonadotropin (hCG), commonly called a “trigger shot,” to induce ovulation approximately 36 hours later. If you are doing timed intercourse, you will be told to have sex around that window. If you are doing IUI, the insemination is scheduled for the day after the trigger.

One factor that can quietly undermine a well-timed letrozole cycle is a premature rise in progesterone. A study of letrozole and clomiphene IUI cycles found that when progesterone on trigger day was 1.5 ng/mL or higher, the ongoing pregnancy rate dropped by more than half compared to cycles where progesterone stayed below 1 ng/mL.¹⁸ This is one reason many clinics check bloodwork on monitoring day: not just to confirm a follicle is ready, but to catch early progesterone rises that suggest the ovulation window may already be closing.

Combining Letrozole With Other Medications

Some women take letrozole on the standard five-day schedule and then add low-dose injectable gonadotropins afterward. This combination is sometimes used for women with PCOS who do not respond adequately to letrozole alone. A meta-analysis of six randomized trials found that combining letrozole with gonadotropins produced significantly higher ovulation and clinical pregnancy rates than letrozole alone in PCOS patients, along with better endometrial thickness and more mature follicles.¹⁹

When letrozole is paired with gonadotropins, it also helps keep the stimulation more controlled. A study comparing letrozole plus human menopausal gonadotropin (HMG) to HMG alone found that the combination produced monofollicular development about 80% of the time, compared to about 55% with HMG alone, and required a lower total gonadotropin dose.²⁰ In combination protocols, the letrozole timing stays the same (five days early in the cycle), and the gonadotropin injections begin after the last letrozole dose.

Luteal Phase Support After a Letrozole Cycle

After ovulation, the second half of your cycle (the luteal phase) needs adequate progesterone to support a potential embryo. There is evidence that adding progesterone supplementation after a letrozole cycle can improve outcomes. A study in women with PCOS found that those who used intravaginal progesterone for luteal support after letrozole-induced ovulation had higher clinical pregnancy rates than those who did not.²¹ Not every clinic prescribes luteal support routinely for oral medication cycles, so this is worth asking about, especially if you have PCOS.

Does Your Ovarian Reserve Change the Equation?

Women with diminished ovarian reserve (often flagged by a low AMH level) sometimes worry that letrozole will not work for them. Interestingly, a large study found that for oral medications like letrozole, ongoing pregnancy rates were comparable between women with low and normal AMH levels at every age bracket studied. Women under 35 with low AMH had ongoing pregnancy rates of about 15% per cycle, virtually identical to the 15% seen in women with normal AMH.²² The gap between low and normal AMH became meaningful only with injectable gonadotropins, where the more aggressive stimulation appears to benefit women whose ovaries have a larger pool of recruitable follicles. This suggests that letrozole’s gentler mechanism, coaxing out one or two good follicles rather than recruiting a large batch, may actually be an equalizer for women with lower reserves.

Why Letrozole’s Short Half-Life Matters for Safety

One common concern is whether letrozole could harm a developing embryo if conception occurs during the same cycle. Letrozole has a short half-life, meaning the drug is largely cleared from your body within a few days of taking the last pill. By the time ovulation occurs (usually a week or more after your final dose) and an embryo could implant (another week after that), the drug is effectively gone. A narrative review of letrozole’s safety profile concluded that its transient estrogen suppression and rapid clearance limit embryonic exposure, supporting a favorable safety profile.²³ The large New England Journal of Medicine trial also found no significant difference in overall congenital anomalies between letrozole and clomiphene groups.⁹

Letrozole for Male Fertility

Though the title question focuses on when women should take letrozole, it is worth knowing that some reproductive urologists prescribe letrozole to men with abnormal sperm parameters. The logic is similar: by blocking aromatase, letrozole reduces the conversion of testosterone to estrogen, tipping the hormonal balance toward higher testosterone. A study of men with low sperm counts, poor motility, or abnormal morphology found that letrozole treatment significantly improved sperm concentration, motility, and normal morphology, while the testosterone-to-estrogen ratio improved dramatically.²⁴ Four of the 20 men in that study achieved spontaneous pregnancies with their partners. For men, letrozole is typically taken daily (not in a five-day burst) and at lower doses, often 2.5 mg every other day or a few times per week, for several months. The dosing schedule is entirely different from the fertility-cycle approach used in women.